Longevity moves personal care toward maintenance and resilience

Tom Whitfield

A 2026 RX Global report finds personal-care ingredient development moving toward biological maintenance, preventative support and long-term functionality. It frames that trajectory as a move away from anti-ageing and reversal. The report supplies research direction, not proof that a personal-care product extends human lifespan.

RX Global, organiser of in-cosmetics Global, developed the document with Euromonitor International. Coachchem sponsored it. Titled The Science Shaping Longevity in Personal Care 2026, it combines industry intelligence, expert commentary and examples of recent ingredient innovation. The supplied summary gives no clinical endpoints, ingredient concentrations or finished-product results.

Perspectives come from leading beauty brands, ingredient suppliers and scientific experts. Named contributors include Shiseido, DECIEM, BASF, Symrise and DSM-Firmenich. Their input covers five areas:

• skin care;
• hair care;
• fragrance;
• nutricosmetics;
• body care.

The report also examines how ingredient technologies and formulation concepts move from global research into practical applications. That breadth can identify strategic themes across categories. It does not, in the supplied material, provide product-level evidence for those links.

What does this change for formulators?

Ina Dawer, Global Insight Manager: Ingredients at Euromonitor International, said: “The strongest signal in longevity is the move away from anti-ageing and reversal, and toward longevity as functional health span.”

That framing shifts the formulation brief from correcting visible damage to supporting biological systems over time. Maintenance and resilience become testable propositions rather than marketing modifiers. The summary does not define the test methods, so formulators still need evidence for each claim.

Biotechnology anchors the report’s technical agenda. Its named themes include:

• precision fermentation;
• microbiome science;
• PDRN;
• exosome-inspired delivery systems;
• biomarker analysis;
• clinical testing.

These technologies may widen formulation choices and improve performance testing. The source gives no comparative trial data, safety assessments or commercial formulations for them.

Consumer expectations also push longevity toward everyday health and wellbeing. The report identifies nutricosmetics, functional ingredients and convenient delivery formats as routes for long-term wellness routines. The supplied summary offers no sales, demographic or uptake data to show how large that demand has become.

Hair health span enters formulation planning

The same logic reaches scalp health, hair care and body care, where longevity is gaining traction. Dawer said: “In beauty, this is showing up through skin span and increasingly hair health span, where the focus is maintaining resilience, recovery and barrier integrity over time.”

She describes ceramides, peptides, antioxidants and microbiome-supporting actives as moving beyond niche hero status and becoming formulation baselines across skin and hair care. She argues that maintenance and resilience will prove more durable than transformation-led marketing claims. That remains a forecast, not comparative market evidence.

For hairdressers and formulators, “hair health span” points to scalp health, resilience, recovery and barrier integrity. The source does not split findings by hair type or texture. Its hair-specific guidance therefore remains general rather than condition-led.

Evidence will decide the commercial claim

The report also connects advances in neuroscience with fragrance innovation, especially the relationship between sensory experiences and emotional wellbeing. That relationship may widen fragrance development beyond conventional mood positioning. No sensory study, ingredient or consumer outcome appears in the supplied summary.

GLP-1 medication use creates additional questions for personal-care innovation, according to the report. The source does not specify those questions or identify effects on skin, hair or body care. Formulators cannot treat the GLP-1 reference as a finished market brief.

The commercial evidence remains thin because the report illustrates global ingredient technologies and formulation concepts without naming a resulting product, price or launch date. Readers can view the report online.

The next test sits in clinical evidence. Biomarker analysis and clinical testing must show whether emerging actives deliver the maintenance, resilience and recovery promised by longevity-led formulation.